摘要
目的探讨18F-FDG双探头符合探测正电子显像在恶性淋巴瘤诊治中的临床应用价值。方法分析经病理确诊的85例淋巴瘤的检查结果,其中11例霍奇金淋巴瘤(HL),74例非霍奇金淋巴瘤(NHL)。结果在淋巴瘤治疗前诊断中,对于淋巴结内病灶与结外病灶18F-FDG双探头符合探测正电子显像检出率分别为96.4%(81/84)、85.7%(24/28),均高于CT、MRI检查检出率(P<0.01)。在评估淋巴瘤治疗前分期上,31例阳性显像患者中,12例临床分期经检查后得以改变,达38.7%,10例(32.3%)临床分期上升,2例(6.5%)临床分期下调,导致8例(25.8%)患者治疗计划发生改变。在判断淋巴瘤治疗后残留复发灶中,18F-FDG双探头符合探测正电子显像对发现残余或复发病灶诊断灵敏度、特异性及正确度分别为77.6%(38/49)、73.5%(25/34)和75.9%(63/83),均高于CT、MRI检查(P<0.01)。结论在淋巴瘤的临床诊断分期及疗效评估方面,18F-FDG双探头符合探测正电子显像具有重要临床意义。
Objective The retrospective analysis about the detecting results of using 18F-fluorodeoxyglucose（FDG） DHCSPECT/CT in the detection of malignant lymphoma was performed to investigate the clinical value of 18F-FDG DHC-SPECT/CT with dual-head coincidence detecting system in the detection of malignant lymphoma.Methods The detecting results of 85 patients histopathologically diagnosed as malignant lymphoma were analyzed.There were 11 patients with hodgkin lymphoma and 74 patients with non-Hodgkin lymphoma.Results During the diagnosis of lymphoma before treatment,the developing detection rate of 18F-FDG DHCSPECT/CT for intralymphatic node focus infection and extralymphatic node focus infection was 96.4%（81 /84） and 85.7 %（24 /28）,which was higher than that of CT and MRI（P 0.01）.The staging of lymphoma before treatment,among 31 patients with masculine display,the clinical staging of 12 patients（38.7%） were corrected;10 patients（32.3%） went up and 2 patients（6.5%） went down.Thus,the treatment plan for 8 patients（25.8%） had to be changed.In determining the residual,recurrent lesions after treatment for lymphoma patients,the diagnostic sensitivity,specificity and accuracy of 18F-FDG DHC-SPECT/CT imaging were 77.6%（38 /49） 、 73.5%（25 /34） 和 75.9%（63 /83）,which were higher than those of CT and MRI detection（P 0.01）.Conclusion 18 F-FDG DHC-SPECT/CT has great clinical significance in clinical diagnosis and curative evaluation.
出处
《白求恩军医学院学报》
2012年第6期461-463,共3页
Journal of Bethune Military Medical College
